References
- Terushkin V, Stern BJ, Judson MA, et al. Neurosarcoidosis: presentations and management. Neurologist 2010;16:2–15.
- Gelfand JM, Bradshaw MJ, Stern B, et al. Infliximab for the treatment of CNS sarcoidosis: a multi-institutional series. Neurology 2017;89:2092–2100.
- Gregg KS, Kauffman CA. Invasive aspergillosis: epidemiology, clinical aspects, and treatment. Semin Respir Crit Care Med. 2015;36:662–672.
- Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis. 2001;32:358–366.
- Orenstein R, Matteson E. Opportunistic infections associated with TNF-a treatment. Future Rheumatol. 2007;2:567–576.
- Bourne EL, Dimou J. Invasive central nervous system aspergillosis in a patient with Crohn’s disease after treatment with infliximab and corticosteroids. J Clin Neurosci. 2016;30:163–164.
- Uzunhan Y, Nunes H, Jeny F, et al. Chronic pulmonary aspergillosis complicating sarcoidosis. Eur Respir J. 2017;49:1602396.
- Jamilloux Y, Cohen-Aubart F, Chapelon-Abric C, et al. Efficacy and safety of tumor necrosis factor antagonists in refractory sarcoidosis: a multicenter study of 132 patients. Seminars Arthritis Rheumatism 2017;47:288–294.
- Cohen Aubart F, Bouvry D, Galanaud D, et al. Long-term outcomes of refractory neurosarcoidosis treated with infliximab. J Neurol. 2017;264:891–897.